Last reviewed · How we verify
2%Chlorhexidine-70%Isopropanol
2% Chlorhexidine-70% Isopropanol, marketed by Poitiers University Hospital, holds a niche position in the antiseptic market. The key composition patent expiring in 2028 provides a temporary barrier to entry, enhancing the drug's competitive advantage. However, the lack of revenue data and primary trial results poses a significant risk in assessing its market performance and potential.
At a glance
| Generic name | 2%Chlorhexidine-70%Isopropanol |
|---|---|
| Sponsor | Poitiers University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Prospective Cohort Study to Evaluate the Safety, Efficacy, and Usability of the EpiZact Device (PHASE4)
- Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery (PHASE4)
- Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination (PHASE3)
- Hub Cleansing to Prevent Hub Infection (NA)
- Efficacy Study Comparing 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2%Chlorhexidine-70%Isopropanol CI brief — competitive landscape report
- 2%Chlorhexidine-70%Isopropanol updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI